First UK NHS patient treated with Iluvien: pSivida
pSivida (ASX:PVA) has announced that the first UK National Health Service (NHS) patient has been treated with Iluvien, less than three months after the product was recommended for reimbursement for a subset of diabetic macular edema (DME) patients.
pSivida’s licensee Alimera Sciences has shipped initial Iluvien orders to several UK NHS facilities, and the first patient was implanted on 10 January.
The UK’s National Institute for Health and Care Excellence (NICE) issued a final guidance to the National Health Service on 27 November, recommending Iluvien for chronic DME patients who have already had cataract surgery and are considered insufficiently responsive to available therapies.
“We are encouraged by the speed with which Iluvien has been made available to NHS facilities,” pSivida CEO Dr Paul Ashton commented. “These recent Iluvien orders reflect the rapid implementation of the final guidance from [NICE].”
Alimera has also secured approval for Iluvien - which uses a micro-insert developed by pSivida - in Europe, but has suffered three separate knockbacks for its New Drug Applications in the US.
pSivida is independently seeking approvals for a product which uses the same micro-insert as Iluvien but is instead designed to treat posterior uveitis.
pSivida (ASX:PVA) shares were trading 11.59% higher at $5.20 as of around 2 pm on Friday.
Three-in-one pill could transform hypertension treatment
Australian research has produced impressive Phase III clinical trial results for an innovative...
AI-designed DNA switches flip genes on and off
The work creates the opportunity to turn the expression of a gene up or down in just one tissue...
Drug delays tumour growth in models of children's liver cancer
A new drug has been shown to delay the growth of tumours and improve survival in hepatoblastoma,...